Nebula Research & Development LLC Has $677,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Nebula Research & Development LLC raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 18.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,759 shares of the biotechnology company’s stock after acquiring an additional 1,230 shares during the period. Nebula Research & Development LLC’s holdings in Blueprint Medicines were worth $677,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Sanctuary Advisors LLC bought a new position in Blueprint Medicines during the third quarter worth about $202,000. Synovus Financial Corp increased its holdings in shares of Blueprint Medicines by 4.0% during the third quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock worth $2,224,000 after buying an additional 922 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after buying an additional 265 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of Blueprint Medicines in the third quarter valued at approximately $3,395,000. Finally, Empirical Asset Management LLC acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $2,348,000.

Insider Buying and Selling at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. This represents a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on BPMC. Jefferies Financial Group began coverage on shares of Blueprint Medicines in a report on Monday, March 17th. They set a “buy” rating and a $135.00 target price for the company. Stephens restated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Piper Sandler raised their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, Wolfe Research initiated coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $124.53.

Blueprint Medicines Trading Up 1.0 %

BPMC opened at $88.51 on Tuesday. The company’s 50 day moving average is $87.46 and its 200-day moving average is $93.18. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.66 billion, a P/E ratio of -81.95 and a beta of 0.75.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.